A 60-year-old man with stage IV, M1c melanoma (adrenal gland lesion of 10 cm in diameter and abdominal lymph node metastases up to 1.9 cm) without evidence of brain metastases following magnetic resonance imaging (MRI) was treated with ipilimumab, monoclonal antibody to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), as second-line therapy in the context of a clinical trial. Earlier he had received first-line treatment with dacarbazine (800 mg/m 2 ) every 28 days combined with interferon-a 2b (3 Mio subcutaneously three times a week) for 2 months. He received ipilimumab 10 mg/kg once every 3 weeks for a total of four cycles (four doses in total) and tolerated this well without any side effects. The treatment was continued because of stabilized disease. After the seventh dose of this therapy, he presented with a severe frontal headache, emesis, ataxia, visual disorders (diplopia, vertical nystagmus), and vertigo. MRI of the brain showed a solitary brain lesion of 2 mm diameter and enlargement of the pituitary gland and stalk (Fig. 1) . Laboratory tests showed low levels of serum cortisol, thyroid-stimulating hormone (TSH), and testosterone (cortisol 2.1 mg/dl, normal range 6-23; TSH 0.07mIU/ml, normal range 0.27-4.2 ; fT4 0.88 ng/dl, normal range 0.9-1.7; fT3 1.6 pg/ml, normal range 2.0-4.4; testosterone < 0.2 ng/ml, normal range 1.5-5.6).
The differential diagnosis included CTLA-4 antibodyinduced autoimmune hypophysitis and metastatic disease to the pituitary gland. Treatment was initiated with dexamethasone 4 mg intravenously every 4-6 h and thyroxine replacement with 25 mg daily. The clinical symptoms recovered rapidly and an MRI scan after 4 days showed a marked reduction in the size of the pituitary gland (Fig. 2) . The suspicion of a CTLA-4 antibodyinduced autoimmune hypophysitis was confirmed. The small brain metastasis was treated with stereotactic surgery. Thyroxine replacement has since been discontinued because of recovery of TSH production. The patient continued to receive hydrocortisone 25 mg replacement until his death because of progressive disease in strong immune response and a second costimulatory signal is required to overcome a threshold. This is provided primarily by CD28 on the T cell that is triggered by the binding to the molecule B7 expressed on the antigen-presenting cells. However, once activated, T cells express a second receptor, CTLA-4 that can also bind the same B7 molecules. Unlike CD28, CTLA-4 inhibits the T cell, blocking the ongoing immune response. Two monoclonal antibodies that inhibit CTLA-4 are currently in clinical development in a number of different tumor types. The most relevant toxicities associated with this are immune events related to stimulation of the immune system [1, 2] . The most frequently reported immune events are diarrhea caused by an autoimmune colitis and dermatitis. Rarely autoimmune hepatitis, uveitis, and hypophysitis have been reported [3] . There is some evidence that patients developing immune breakthrough events have a better outcome [3] . These events are sometimes serious or potentially fatal, and may require treatment with high-dose corticosteroids and other immunosuppressant therapies.
For patients with autoimmune hypophysitis, radiological changes appear to predate the development of clinical symptoms [4] . Histological examination of the pituitary gland shows typically an infiltration by lymphocytes, plasma cells, and macrophages. The pituitary gland seems to be a target for autoimmunity although the pathogenesis remains unclear. Hypophysitis may cause impairment of pituitary function, with low levels of adrenocorticotropic hormone, TSH, and gonadotrophins, resulting in low levels of T4, cortisol, and testosterone [3] . Although the symptoms of pituitary failure may be nonspecific, the enlargement of the hypophysis may cause headache and visual impairment [3] . In rare cases, autoimmune hypophysitis also involves the neurohypophysis with clinical signs of diabetes insipidus.
In contrast to other autoimmune events, where short courses of high-dose steroids lead to a complete resolution of symptoms, permanent hormone substitution with physiological doses of steroids may be necessary for patients with an autoimmune hypophysitis. Careful consideration of pituitary function should preceed the discontinuation of hydrocortisone. There is no clear evidence that the use of low-dose steroid therapy adversely impacts on CTLA-4 treatment efficacy [2, 3] .
The presenting symptoms of immune-mediated hypophysitis may be subtile and clinicians need a high index of suspicion. Early imaging with an MRI scan can detect pituitary enlargement before the onset of complete pituitary failure, ensuring timely treatment of this potentially serious complication.
